Storia in 2 fonti

Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Merck & Co (NYSE:MRK), Gilead Sciences (NAS

Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.

Raccontata da

fiercepharma.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 g fa

Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Merck & Co (NYSE:MRK), Gilead Sciences (NAS

Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.

originale

fiercepharma.com1 g fa

Gilead, Merck’s phase 3 data back first weekly HIV pill

Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what it takes to become the first complete weekly pill for the treatme | Detailed phase 3…

Leggi questa versione → originale

Timeline cronologica

martedì 21 luglio 2026·fiercepharma.com
Gilead, Merck’s phase 3 data back first weekly HIV pill
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what it takes to become the first complete weekly pill…
martedì 21 luglio 2026·benzinga.com
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Merck & Co (NYSE:MRK), Gilead Sciences (NAS
Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.